Francisco Partners Iv, L.P. Sells 274,717 Shares of GoodRx (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 274,717 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $3.50, for a total value of $961,509.50. Following the transaction, the insider owned 777,213 shares in the company, valued at $2,720,245.50. The trade was a 26.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The shares were sold at an average price of $3.53, for a total transaction of $1,666,071.75.

GoodRx Stock Down 3.1%

Shares of GoodRx stock traded down $0.11 during trading on Friday, reaching $3.45. 1,746,243 shares of the company traded hands, compared to its average volume of 1,833,117. The firm has a market capitalization of $1.18 billion, a PE ratio of 86.27, a P/E/G ratio of 1.77 and a beta of 1.60. GoodRx Holdings, Inc. has a 1-year low of $1.77 and a 1-year high of $5.81. The company has a 50 day moving average price of $3.13 and a 200-day moving average price of $2.63. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, hitting analysts’ consensus estimates of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business had revenue of $200.41 million during the quarter, compared to analysts’ expectations of $193.23 million. During the same period last year, the company posted $0.09 earnings per share. The business’s quarterly revenue was down 1.3% on a year-over-year basis. As a group, equities research analysts expect that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

GDRX has been the subject of several research reports. TD Cowen raised their target price on GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Leerink Partners set a $5.00 price target on GoodRx in a research note on Thursday, August 6th. Barclays increased their price target on GoodRx from $3.00 to $4.00 and gave the stock an “underweight” rating in a report on Thursday. Citigroup raised their price objective on GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $4.00 price objective on shares of GoodRx in a report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $4.23.

Institutional Investors Weigh In On GoodRx

Several institutional investors have recently bought and sold shares of the stock. Lazard Asset Management LLC lifted its stake in GoodRx by 43.6% during the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock valued at $85,000 after acquiring an additional 5,201 shares in the last quarter. Brevan Howard Capital Management LP grew its stake in shares of GoodRx by 7.7% in the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock worth $404,000 after acquiring an additional 6,842 shares in the last quarter. Hirtle Callaghan & Co LLC grew its stake in shares of GoodRx by 60.3% in the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock worth $49,000 after acquiring an additional 6,869 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of GoodRx by 202.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock worth $56,000 after acquiring an additional 7,580 shares in the last quarter. Finally, Quarry LP purchased a new stake in shares of GoodRx in the third quarter valued at about $33,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.